New combination of drugs works together to reduce lung tumors in mice

LA JOLLA—Cancer treatments have long been moving toward personalization—finding the right drugs that work for a patient’s unique tumor, based on specific genetic and molecular patterns. Many of these targeted therapies are highly effective, but aren’t available for all cancers, including non-small cell lung cancers (NSCLCs) that have an LKB1 genetic mutation. A new study led by Salk Institute Professor Reuben Shaw and former postdoctoral fellow Lillian Eichner, now an assistant professor at Northwestern University, revealed FDA-approved trametinib and entinostat (which is currently in clinical trials) can be given in tandem to produce fewer and smaller tumors in mice with LKB1-mutated NSCLC.

Left: Lung tissue of mice with LKB1-mutated non-small cell lung cancer. Right: Lung tissue after being treated with both trametinib and entinostat showing smaller and fewer tumors.
Left: Lung tissue of mice with LKB1-mutated non-small cell lung cancer….
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks